In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with expert Prof. Dr. Thomas Hammerschmidt, to dive deep into Germany’s evolving AMNOG framework and what it really means for pharmaceutical pricing. 

This insightful conversation explores key changes in Germany’s pharma landscape, including the shift from negotiation-based pricing to benefit-linked guardrails, the 5% clinical trial rule, and their impact on innovation and reimbursement strategy. A must-listen for pharma professionals, health economists, and market access leaders!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #PharmaPricing #AMNOG #Reimbursement #Germany #HTA #PharmaStrategy #marketaccess #marketaccesspodcast